Phase 4 N=10 Performance of Junctional Tourniquets in Normal Human Volunteers
Hemorrhage
Primary: Effectiveness at Stopping Distal Pulse — 97; 27; 83; 93 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=24 Healthy Adult Volunteer Study of Intraosseous Infusion Using the Sternum
Intraosseous Vascular Access
Primary: Occurrences of Extravasation During Infusion — 2 participants
Early Phase 1 N=6 VAC069: A Study of Blood-stage Controlled Human P. Vivax Infection
Malaria, Vivax
Primary: Number of Participants With Serious Adverse Events — 1 Participants
Phase 3 N=24,111 Evaluation of a Human Immunodeficiency Virus (HIV) Blood Screening Assay
Healthy Donors · HIV Positive
Primary: PRISM HIV O Plus Test Data for Specificity — 10; 15589 participants
N/A N=20 Head Stabilization of Healthy Volunteers
Healthy
Primary: Collection of Head Motion Data to be Used in Developing Head Stabilization Methods in Brain Radiation Patients — 95 % of time within tolerance
Phase 1 N=20 Dengue 4 Human Infection Model (Dengue CVD 11000; DHIM-4)
Dengue
Primary: Number of Participants With Solicited Injection Site Adverse Events — 1; 0 Participants
Phase 4 N=3,032 VA-008 ACAM2000® Vaccination of Plasma Donors for the Production of VIGIV
Smallpox Vaccine Adverse Reaction
Primary: Number of Vaccinated Participants With Adverse Events (AEs) Including Serious Adverse Events (SAEs) — 1420 Participants
N/A N=978 Health Education Model Led by Community Health Volunteers.
Schistosomiasis · Health Education
Primary: Change in Infection Rate — 47; 35; 3; 6 Number of Participants with S. haematobi
Phase 2 N=88 A Challenge Study to Assess the Safety, Immunogenicity and Efficacy of a Malaria Vaccine Candidate
Malaria
Primary: Efficacy of the RH5.1/AS01 Vaccine by Demonstrating a Reduced PMR in Vaccinated Subjects Compared to Infectivity Controls Against 3D7 Clone Parasites in a CHMI Model…
Phase 2 N=18 Evaluation of Reproducibility of a Sporozoite Challenge Model for Plasmodium Vivax in Human Volunteers
MALARIA · FEVER · Sweating Fever
Primary: Infection for P. Vivax — 11; 11; 9 days
N/A N=75 Testing of a Valsalva Assist Device (VAD) in Healthy Volunteers Performing a Valsalva Manoeuvre
SVT · Vagal Bradycardia
Primary: Assessing Heart Rate During the Supine and Modified VM and Assessing Heart Rate While Using the VAD and Manometer — 33.6; 25.9; 28.7; 30.8 beat per minute — p=<0.001
Phase 1 N=50 Open-label Safety and Tolerability Study of CoVaccine HT™ in Healthy Volunteers
Vaccine
Primary: Safety Events — 20; 0; 40; 50 percentage of patients
N/A N=21 Evaluation of Vision-Guided Shared Control for Assistive Robotics Manipulators
Spinal Cord Injury/Disorder
Primary: Task Completion Time — 333.7; 604.7; 748.5; 1128.9 seconds
Phase 2 N=115 VSV-ZEBOV Geneva Vaccine Trial
Ebolavirus Disease
Primary: Titers of ZEBOV-specific IgG Antibodies — 1227; 25; 344.5 ELISA units per ml
N/A N=120 Clearblue Home Pregnancy Test Consumer Study
Pregnancy
Primary: Consumer Agreement — 100 percentage of agreement
Phase 1 N=8 First-in-Human Study to Assess the Safety, Tolerability and Pharmacokinetics of MMV367
Malaria,Falciparum
Primary: Number of Treatment-Emergent Adverse Events (TEAEs) — 1; 4; 5; 1 Number of events
N/A N=22 Survival and Recovery of Radio-labeled Platelets Derived From Mirasol-treated Whole Blood
Blood Safety
Primary: Platelet 24-hour Relative Recovery — 43.31; 52.01 Percentage of platelet count
N/A N=11 Teleoperation Experimental Comparison With Able-bodied Subjects
Amputation; Traumatic, Arm, Upper
Primary: Transfer Success Rate in a Fragile Box and Blocks Task — 67.50; 72.75; 93.46; 95.06 percentage of attempted transfers — p=<0.001
Phase 1 N=10 ADVP005; Dengue CVD 12000 - Dengue-1-Virus Live Virus Human Challenge (DENV-1-LVHC)
Dengue
Primary: Number of Participants With Solicited Injection Site Adverse Events — 0; 1 Participants
N/A N=36 COVID-19 SARS-CoV-2 Screening Protocol
Covid19
Primary: Participants Enrolled — 36 Participants
N/A N=18 Production of a Device to Obtain Continuous Ambulatory Vestibular Assessment (CAVA) - Healthy Volunteer Trial
Optokinetic Nystagmus
Primary: Sensitivity and Specificity of a Computer Algorithm to Detect Artificially Induced Nystagmus — 99.1; 98.6 Percent
N/A N=20 Engineering Evaluation of the Helix Ventilator
Respiratory Disease · Pulmonary Disease · Pediatric ALL
Primary: Proximal Pressure From Trilogy Evo Ventilator and Current Device — 8.3; 8.2 cm H2O
N/A N=20 Wearable Dark-adaptometer in Normal Adult Healthy Volunteers
Photoreceptor Sensitivity Thresholds
Primary: Time to Rod-cone Break (RCB) — 11.34; 9.98 Minutes
Phase 1 N=9 MMV533 Plasmodium Falciparum Volunteer Infection Study
Malaria
Primary: The Activity of Single Oral Doses of MMV533 (Name of Investigational Medicinal Product) on Clearance of Plasmodium — 42.17; 158.03; 187.57 PRR48=parasite reduction ratio…
Phase 1 N=56 Safety, Tolerability, Pharmacokinetic Characteristics of hzVSF-v13 in Healthy Male Volunteers
Healthy
Primary: Safety and Tolerability Assessments by Vital Signs — 3; 3; 6; 6 Participants
N/A N=72 Don't Throw Your Heart Away: Clinician Study 3
Cardiac Transplant Disorder
Primary: Hospital Choice — 4; 21; 34; 13 Participants
N/A N=105 Don't Throw Your Heart Away: Medical Student Study 2
Cardiac Transplant Disorder
Primary: Hospital Choice — 33; 47; 23; 2 Participants
Phase 4 N=44 Eovist vs. Dotarem Healthy Volunteer MRI
Transient Severe Arterial Phase Motion
Primary: Subject Breath Hold Capacity, as Measured by Number of Seconds a Subject Can Hold His/Her Breath — 28; 38; 35 seconds
Phase 1 N=41 A Study of OsrHSA in Adult Healthy Male and Female Volunteers
Ascites Hepatic
Primary: Incidence of Treatment-Emergent Adverse Events — 1; 0; 2; 1 Participants
Phase 2 N=20 Safety/Immunogenicity/Genetic Drift of MP-12 Rift Valley Fever Vaccine
Rift Valley Fever
Primary: Safety as Measured by the Number of Adverse Events — 22; 130 AEs